Precipio, Inc. (PRPO): Price and Financial Metrics
GET POWR RATINGS... FREE!
PRPO Stock Summary
- With a market capitalization of $18,825,817, PRECIPIO INC has a greater market value than merely 6.24% of US stocks.
- Of note is the ratio of PRECIPIO INC's sales and general administrative expense to its total operating expenses; 86.6% of US stocks have a lower such ratio.
- For PRPO, its debt to operating expenses ratio is greater than that reported by only 14.16% of US equities we're observing.
- Stocks that are quantitatively similar to PRPO, based on their financial statements, market capitalization, and price volatility, are OPRX, LEV, ASLE, XOMA, and WNS.
- PRPO's SEC filings can be seen here. And to visit PRECIPIO INC's official web site, go to www.precipiodx.com.
PRPO Valuation Summary
- PRPO's EV/EBIT ratio is -1.1; this is 113.75% lower than that of the median Healthcare stock.
- Over the past 243 months, PRPO's EV/EBIT ratio has gone up 5.9.
Below are key valuation metrics over time for PRPO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| PRPO | 2022-09-23 | 1.9 | 0.9 | -1.6 | -1.1 |
| PRPO | 2022-09-22 | 2.0 | 0.9 | -1.8 | -1.2 |
| PRPO | 2022-09-21 | 2.1 | 1.0 | -1.9 | -1.3 |
| PRPO | 2022-09-20 | 2.2 | 1.0 | -2.0 | -1.4 |
| PRPO | 2022-09-19 | 2.4 | 1.1 | -2.1 | -1.5 |
| PRPO | 2022-09-16 | 2.3 | 1.0 | -2.0 | -1.4 |
PRPO Growth Metrics
- Its year over year price growth rate is now at -74.75%.
- Its 3 year net income to common stockholders growth rate is now at 25.28%.
- Its 4 year net cashflow from operations growth rate is now at -35.67%.
The table below shows PRPO's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-06-30 | 9.487 | -7.509 | -10.799 |
| 2022-03-31 | 9.472 | -7.622 | -11.668 |
| 2021-12-31 | 8.849 | -6.577 | -8.53 |
| 2021-09-30 | 8.355 | -6.628 | -8.194 |
| 2021-06-30 | 7.736 | -6.92 | -9.636 |
| 2021-03-31 | 6.7 | -7.134 | -8.872 |
PRPO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- PRPO has a Quality Grade of D, ranking ahead of 7.61% of graded US stocks.
- PRPO's asset turnover comes in at 0.324 -- ranking 58th of 76 Measuring and Control Equipment stocks.
- ROP, AXDX, and TMO are the stocks whose asset turnover ratios are most correlated with PRPO.
The table below shows PRPO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.324 | 0.268 | 19.897 |
| 2021-03-31 | 0.331 | 0.223 | 15.583 |
| 2020-12-31 | 0.307 | 0.189 | 14.223 |
| 2020-09-30 | 0.247 | 0.135 | 15.678 |
| 2020-06-30 | 0.200 | 0.076 | 11.555 |
| 2020-03-31 | 0.174 | 0.084 | 12.523 |
PRPO Price Target
For more insight on analysts targets of PRPO, see our PRPO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $7.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
PRPO Stock Price Chart Interactive Chart >
PRPO Price/Volume Stats
| Current price | $0.80 | 52-week high | $2.83 |
| Prev. close | $0.86 | 52-week low | $0.77 |
| Day low | $0.80 | Volume | 36,691 |
| Day high | $0.86 | Avg. volume | 203,272 |
| 50-day MA | $1.17 | Dividend yield | N/A |
| 200-day MA | $1.26 | Market Cap | 18.28M |
Precipio, Inc. (PRPO) Company Bio
Precipio, Inc. operates as a biotechnology company. The Company offers medicines for oncology, cardiology, neurology, and inherited diseases. Precipio also provides specialized clinical and research services to biopharmaceutical companies developing targeted therapies. Precipio serves customers in the United States.
Latest PRPO News From Around the Web
Below are the latest news stories about PRECIPIO INC that investors may wish to consider to help them evaluate PRPO as an investment opportunity.
Precipio Signs Agreement with Another Major US Healthcare Distributor for HemeScreen™Adding customer segment exceeding $100M in market potentialNEW HAVEN, Conn., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), has signed a distribution agreement for HemeScreen with a major distribution partner (name withheld as per partner’s policy). Following an upcoming training program and onboarding of their national coverage, this distribution channel partner’s sales team will begin promoting and driving sales of the HemeScreen platform |
Sharon Robins Joins Precipio’s Products Division as Senior Director of Laboratory & Hospital SalesPrecipio continues to build strong team in anticipation of substantial growth in the next 12 monthsNEW HAVEN, Conn., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), welcomes Sharon Robins as the Company’s Senior Director of Laboratory & Hospital Sales for the Product’s Division. As the Company launches HemeScreen with ThermoFisher and its 200+ member sales force, and with the goal of Thermo meeting its first-year target of $10M in revenues (a |
Precipio (PRPO) Gets a Buy from Maxim GroupE ratio of -2.82. |
Precipio Launches New 1-Step Technology for all HemeScreen AssaysNew technology enables same day test results by eliminating extra confirmation stepNEW HAVEN, Conn., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces the launch of its second generation of HemeScreen panels. Precipio’s customers using HemeScreen in their laboratory will have the option of upgrading to the 1-step assay, or remaining with the current assay. While the first generation of panels required a 2-step process that included a |
Toni-Ann Mills Joins Precipio’s Products Division to Lead Channel Partner Training, Learning & DevelopmentPrecipio prepares to launch a nationwide HemeScreen sales effort of 250+ sales reps from AmerisourceBergen, ThermoFisher, and other distributorsNEW HAVEN, Conn., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), welcomes Toni-Ann Mills as the Company’s Senior Director for Learning & Development. With a ~$0.5B market potential for HemeScreen, Precipio is preparing to mobilize all resources towards capturing significant market share. As Precipio |
PRPO Price Returns
| 1-mo | -32.20% |
| 3-mo | -27.93% |
| 6-mo | -42.03% |
| 1-year | -71.63% |
| 3-year | -67.35% |
| 5-year | -97.53% |
| YTD | -49.37% |
| 2021 | -23.67% |
| 2020 | 0.98% |
| 2019 | -8.89% |
| 2018 | -87.50% |
| 2017 | -85.71% |
Continue Researching PRPO
Want to see what other sources are saying about Precipio Inc's financials and stock price? Try the links below:Precipio Inc (PRPO) Stock Price | Nasdaq
Precipio Inc (PRPO) Stock Quote, History and News - Yahoo Finance
Precipio Inc (PRPO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...